玻璃体腔内注射康柏西普治疗黄斑部小分支视网膜静脉阻塞导致的黄斑水肿

目的：评价玻璃体腔内注射康柏西普治疗黄斑部小分支视网膜静脉阻塞继发黄斑水肿的有效性及安全性。

方法：回顾性分析2015-07/2016-09在我院确诊为黄斑小分支视网膜静脉阻塞继发黄斑囊样水肿的患者资料19例19眼，所有患者均按3+按需注射(pro re nata，PRN)的方法行玻璃体腔内注射康柏西普0.05mL(0.5mg)，每月随诊观察最佳矫正视力、中央视网膜厚度、注射次数及眼部相关并发症等。

结果：治疗后1、2、3、6mo的最佳矫正视力与治疗前相比均有改善，差异具有统计学意义(P<0.01)； 治疗后1、2、3、6mo的黄斑中心凹厚度与治疗前相比均下降，差异具有统计学意义(P<0.01)； 其中有3眼出现反复发作的黄斑水肿，FFA检查显示微血管瘤渗漏，给予局部光凝封闭血管瘤后水肿吸收； 治疗及随诊期间所有患者均未出现玻璃体出血、视网膜脱离、持续高眼压和眼内炎等并发症。

结论：玻璃体腔注射康柏西普治疗黄斑小分支静脉阻塞继发的黄斑水肿安全有效，可以明显改善视力，减轻黄斑水肿； 顽固的黄斑水肿建议行FFA检查，如水肿为微血管瘤渗漏造成建议联合局部光凝治疗。

Efficacy of intravitreal Conbercept injection for macular edema secondary to macular branch retinal vein occlusion

AIM: To evaluate the efficacy and safety of intravitreous injection of Conbercept for macular edema secondary to macular branch retinal vein occlusion(MBRVO).

METHODS: Clinical records of 19 patients(19 eyes)who were diagnosed MBRVO with macular edema(ME)in our hospital, from July 2015 to September 2016 were retrospectively analysed. All patients were treated with an intravitreal dose of 0.5mg or 0.05mL conbercept ophthalmic injection by the 3+ pro re nata(PRN)project. All patients were evaluated by best corrected visual acuity(BCVA), central retinal thickness(CRT), the number of the injection, and the complications.

RESULTS: During the 1, 2, 3 and 6mo after treatment the mean BCVA all improved significantly(P<0.01), and the mean CRT reduced statistical significantly(P<0.01); 3 eyes had refractory ME, and micro-aneurysm leakage were identified by FFA, and the ME was suppressed effectively after local laser photocoagulation. No complications, such as secondary vitreous haemorrhage, retinal detachment, persistent high intraocular pressure and endophthalmitis were observed during subsequent follow-up.

CONCLUSION: Intravitreous injection of conbercept for macular edema secondary to MBRVO may reduce macular edema and improve visual acuity effectively and safely in the short term.